Obviousness

Obviousness Analysis of US Patent 8,273,735 Under 35 U.S.C. § 103

This analysis evaluates the obviousness of US Patent 8,273,735, which describes processes for preparing benzazepine compounds or salts thereof, under 35 U.S.C. § 103, considering the relevant prior art and the established legal precedent from the Federal Circuit.

Person Having Ordinary Skill in the Art (PHOSITA)

A person having ordinary skill in the art (PHOSITA) for US Patent 8,273,735 would likely be an organic chemist or a chemical engineer with experience in pharmaceutical synthesis, particularly in the development and optimization of synthetic routes for nitrogen-containing heterocyclic compounds, such as benzazepines. This individual would possess knowledge of common synthetic methodologies, reaction conditions, catalysts, and purification techniques, as well as an understanding of how to achieve high yields and purity in industrial-scale chemical production. They would also be familiar with literature concerning vasopressin antagonists and their synthesis.

Prior Art References

The following prior art references are considered in this obviousness analysis:

1. JP-A-4-154765 (JP '765): This Japanese patent application, published June 1, 1992, describes certain benzazepine compounds, including 2,3,4,5-tetrahydro-1H-1-benzazepine compounds and their salts, and identifies their utility as vasopressin antagonists. US8273735 explicitly references JP-A-4-154765 for disclosing the pharmaceutically active benzazepine compound (10) and the intermediate benzoic acid compounds (4), indicating that the end products and some intermediates of the claimed processes were known in the art.
2. Yasuhiro Torisawa et al., Bioorganic & Medicinal Chemistry Letters, 10 (2000), pp. 2493-2495 (Torisawa 2000): This scientific publication is explicitly cited in US8273735 as disclosing a known process (Reaction Scheme C) for preparing the benzoic acid compounds of Formula (4).
3. Kondo's 1999 paper: While the full citation is not provided in the authoritative patent text snippets, the litigation summary clearly states that "the asserted method claims [of US8273735] were found invalid as obvious over Kondo's 1999 paper" by a district court, a finding affirmed by the Federal Circuit in Otsuka Pharmaceutical Co. v. Lupin Ltd.. This paper is particularly relevant to the reduction step involving hydrogenating agents and specific molar equivalents. For the purpose of this analysis, it is assumed that Kondo's 1999 paper, as determined by the Federal Circuit, describes or suggests aspects of the reduction process for benzazepine compounds.

Analysis of Independent Claims under 35 U.S.C. § 103

Claim 1: Process for Preparing Benzazepine Compound (1)

Claim 1 describes a process for preparing a benzazepine compound of Formula (1) or its salt by reacting a compound of Formula (2) with an amide compound of Formula (3) or its salt in the presence of a carbonylating agent.

• Combination: JP-A-4-154765.
• Reasoning: JP-A-4-154765 establishes that benzazepine compounds like (1) were known and useful as intermediates for vasopressin antagonists. If JP-A-4-154765 (or other prior art) generally taught or suggested the construction of such a benzazepine core from an amino-benzazepine (2) and a substituted benzamide derivative (3) via a carbonylation reaction, a PHOSITA would have a motivation to combine these known elements. The patent itself states that compound (2) can be produced by any known process. The broad nature of "reacting... in the presence of a carbonylating agent" might be considered a conventional amidation or acylation strategy for forming the amide bond linking the benzazepine and benzoic acid moieties if similar reactions are generally known in the art for synthesizing such structures. However, without specific details from JP-A-4-154765 or other references on the exact mechanism or conditions for forming compound (1) via this specific coupling, a direct finding of obviousness purely based on JP-A-4-154765 is not fully supported by the provided patent text. The patent asserts its process provides "high yield and high purity", implying an improvement over existing methods. If prior art teaches the general structure and the desirability of creating such a bond, the motivation would be to find an efficient method to do so.

Claims 7, 8, 9, and 10: Processes for Preparing Benzoic Acid Compound (4)

These claims detail four different processes for preparing the benzoic acid compound of Formula (4) or its salt, which is an intermediate for the pharmaceutically active benzazepine compound:

• Claim 7: Reacting an amide compound (11) with an oxalyl halide (19).

• Claim 8: Oxidizing an amide compound (12).

• Claim 9: Hydrolyzing an amide compound (13).

• Claim 10: Oxidizing an amide compound (14).

• Combination: JP-A-4-154765 and Torisawa 2000.

• Reasoning: JP-A-4-154765 identifies compound (4) as a useful intermediate. Torisawa 2000 is explicitly cited in US8273735 as disclosing a known process (Reaction Scheme C) for preparing these benzoic acid compounds (4). Given that a known method for preparing compound (4) already existed (Torisawa 2000), a PHOSITA would be motivated to explore alternative or improved synthetic routes (as claimed in Claims 7-10) to achieve advantages such as higher yield, purity, cost-effectiveness, or ease of industrial scale-up.

  • Motivation for modification: If Torisawa 2000 discloses one method for preparing compound (4), and other methods (oxidation, hydrolysis, reaction with oxalyl halide) are generally known in organic synthesis for converting structurally similar precursors to carboxylic acids, a PHOSITA would have a reasonable expectation of success in applying these standard transformations. For example, oxidizing an appropriate precursor (12 or 14) to a carboxylic acid (4) is a fundamental organic reaction. Similarly, hydrolyzing an ester or nitrile (13) to a carboxylic acid (4) is a common synthetic pathway. Reacting an amide (11) with an oxalyl halide (19) to form a carboxylic acid might also be a known coupling reaction or a variation thereof. The motivation would be to overcome perceived disadvantages of the Torisawa 2000 method, such as low yield, difficult purification, or use of expensive/hazardous reagents.

Claim 11: Process for Preparing 2,3,4,5-tetrahydro-1H-1-benzazepine Compound (10)

Claim 11 describes a process for preparing compound (10) by reducing a benzazepine compound of Formula (1) or its salt in the presence of a hydrogenating agent, specifically using the hydrogenating agent in an amount of 0.1 to 1 mole per 1 mole of compound (1). The claim further specifies hydrogenating agents such as lithium aluminum hydride, sodium borohydride, zinc borohydride, or diborane.

• Combination: JP-A-4-154765 and Kondo's 1999 paper.
• Reasoning: JP-A-4-154765 established the utility and existence of compound (10) as a vasopressin antagonist. The conversion of compound (1) to compound (10) involves a reduction reaction, which is a common synthetic transformation in organic chemistry.
  • Judicial Precedent: The Federal Circuit's affirmance that the asserted method claims (including this reduction step) were invalid as obvious over Kondo's 1999 paper is highly significant. The court's finding indicates that Kondo's 1999 paper either explicitly disclosed or rendered obvious the specific limitation of using a hydrogenating agent in an amount of 0.1 to 1 mole per 1 mole of compound (1).
  • Motivation: The US8273735 patent emphasizes that this specific molar ratio (0.1 to 1 mole, preferably 0.25 to 1 mole, more preferably 0.25 to 0.5 mole for sodium borohydride) is crucial for producing compound (10) in "high yield and high purity" and "with hardly occurring undesirable dehalogenating reaction which has been occurred in the known processes". A PHOSITA, aware of the general reduction of similar compounds (e.g., from Kondo's 1999 paper or other literature on reducing benzazepines) and facing challenges with impurities or dehalogenation, would be motivated to optimize reaction conditions, including the stoichiometry of the reducing agent. Experimentation to find optimal molar ratios to achieve better purity and yield, particularly to avoid side reactions like dehalogenation, would be well within the skill of a PHOSITA. Kondo's 1999 paper, as interpreted by the court, would have provided sufficient teaching or suggestion to motivate this optimization and render the claimed range obvious.

Conclusion

Based on the analysis, particularly in light of the Federal Circuit's ruling regarding Kondo's 1999 paper:

• Claim 11 is highly likely to be obvious over a combination of JP-A-4-154765 (for the known compound and its utility) and Kondo's 1999 paper (for teaching or suggesting the reduction method and optimal stoichiometry for purity/yield, including the specified molar ratio of the hydrogenating agent). A PHOSITA would have been motivated to optimize the reduction conditions to improve yield and purity and to minimize side reactions, with a reasonable expectation of success given the teachings of Kondo's 1999 paper.
• Claims 7, 8, 9, and 10, directed to alternative processes for preparing intermediate compound (4), are also likely obvious over a combination of JP-A-4-154765 (for the known intermediate) and Torisawa 2000 (for a known method of preparation). A PHOSITA would be motivated to explore conventional synthetic transformations (oxidation, hydrolysis, reaction with oxalyl halide) to find improved or more efficient routes for known intermediates, given the existing knowledge of the compound's structure and its role in the synthesis of known active pharmaceutical ingredients.
• Claim 1 (process for preparing compound (1)) may also be obvious if the reaction of compound (2) with compound (3) in the presence of a carbonylating agent represents a conventional amide bond formation from known precursors. However, without more specific details from the cited prior art regarding this particular coupling, a definitive conclusion is more challenging. If the components (2) and (3) are known intermediates, and amide formation via carbonylation is a common synthetic strategy, a PHOSITA would have been motivated to combine these elements to form the known compound (1).

In summary, the key aspect of obviousness for US8273735 revolves around the optimization of known reactions and the application of standard synthetic methodologies to produce known compounds or intermediates, especially as affirmed by the Federal Circuit's finding on the reduction step (Claim 11) over Kondo's 1999 paper.

External Resources Cited:
US8273735B2 - Process for preparing benzazepine compounds or salts thereof - Google Patents. https://patents.google.com/patent/[US8273735B2](/patent/US8273735B2)/en (Accessed 2026-05-22).